Segment Information (Schedule Of Total Revenues Of Top Selling Products) (Details) (USD $) In Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2011		Jun. 30, 2010		Jun. 30, 2011		Jun. 30, 2010
Revenues	$ 224,188		$ 255,474		$ 457,140		$ 547,406
Par Pharmaceutical [Member]
Revenues	202,449		231,938		412,193		503,977
Par Pharmaceutical [Member] | Metoprolol Succinate ER (Toprol-XL) [Member]
Revenues	63,706		119,596		127,124		302,887
Par Pharmaceutical [Member] | Budesonide (Entocort EC) [Member]
Revenues	16,357				16,357
Par Pharmaceutical [Member] | Sumatriptan Succinate Injection (Imitrex) [Member]
Revenues	15,284		17,463		31,983		34,747
Par Pharmaceutical [Member] | Propafenone (Rythmol SR) [Member]
Revenues	13,311				35,350
Par Pharmaceutical [Member] | Amlodipine And Benazepril HCI (Lotrel) [Member]
Revenues	12,505				30,675
Par Pharmaceutical [Member] | Dronabinol (Marinol) [Member]
Revenues	8,118		7,183		14,989		11,274
Par Pharmaceutical [Member] | Chlorpheniramine/Hydrocodone (Tussionex) [Member]
Revenues	7,022				19,701
Par Pharmaceutical [Member] | Tramadol ER (Ultracet ER) [Member]
Revenues	5,873		5,676		11,954		10,962
Par Pharmaceutical [Member] | Meclizine Hydrochloride (Antivert) [Member]
Revenues	4,562		9,398		9,437		19,552
Par Pharmaceutical [Member] | Cholestyramine Powder (Questran) [Member]
Revenues	4,077		2,974		7,760		6,910
Par Pharmaceutical [Member] | Nateglinide [Member]
Revenues	3,815		3,470		8,120		4,988
Par Pharmaceutical [Member] | Cabergoline (Dostinex) [Member]
Revenues	2,920		2,520		5,873		6,514
Par Pharmaceutical [Member] | Methimazole (Tapazole) [Member]
Revenues	2,456		2,590		4,560		5,430
Par Pharmaceutical [Member] | Clonidine TDS (Catapres TTS) [Member]
Revenues			26,290		4,793		44,751
Par Pharmaceutical [Member] | Other [Member]
Revenues	33,398	[1]	31,679	[1]	66,583	[1]	51,709	[1]
Par Pharmaceutical [Member] | Other Product Related Revenues [Member]
Revenues	9,045	[2]	3,099	[2]	16,934	[2]	4,253	[2]
Par Pharmaceutical [Member] | Total Par Pharmaceutical [Member]
Revenues	202,449		231,938		412,193		503,977
OravigTM [Member] | Strativa [Member]
Revenues	1,027				1,776
Zuplenz [Member] | Strativa [Member]
Revenues	263				485
Strativa [Member]
Revenues	21,739		23,536		44,947		43,429
Strativa [Member] | Other Product Related Revenues [Member]
Revenues	125	[2]	3,636	[2]	4,399	[2]	6,136	[2]
Strativa [Member] | Megace ES [Member]
Revenues	14,050		15,493		28,135		29,291
Strativa [Member] | Nascobal Nasal Spray [Member]
Revenues	6,274		4,407		10,152		8,002
Strativa [Member] | Total Strativa [Member]
Revenues	$ 21,739		$ 23,536		$ 44,947		$ 43,429

[1] The further detailing of revenues of the other approximately 60 generic drugs is impracticable due to the low volume of revenues associated with each of these generic products. No single product in the other category is in excess of 3% of total generic revenues for six-month periods ended June 30, 2011 or June 30, 2010.

[2] Other product related revenues represents licensing and royalty related revenues from profit sharing agreements related to products such as diazepam rectal gel, the generic version of Diastat®, and fenofibrate, the generic version of Tricor®. Other product related revenues included in the Strativa segment related to a co-promotion arrangement with Solvay for Androgel® in 2010. This co-promotion arrangement with Solvay was terminated in December 2010 for an associated $2 million payment. During the six-month period ended June 30, 2011, Strativa earned $4.3 million of royalty income from its share of the proceeds from Optimer Pharmaceuticals' sale of certain rights in fidaxomicin to a third party. Under the terms of the 2007 termination agreement, we are also entitled to royalty payments on future sales of fidaxomicin.